We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
TNDM Stock Gains on the Commercial Launch of Control-IQ+ Technology
Read MoreHide Full Article
Tandem Diabetes Care, Inc. (TNDM - Free Report) recently commercially launched Control-IQ+ technology - the latest generation of its advanced hybrid closed-loop algorithm in the United States. Control-IQ+ is compatible with both the t:slim X2 insulin pump and Tandem Mobi System. It is available for people with type 1 diabetes (ages 2 years and older) and adults with type 2 diabetes.
TNDM Stock’s Likely Trend Following the News
Since the announcement, TNDM’s shares edged up 1.1% at the after-market trading yesterday.
Tandem Diabetes continues to strategically expand the adoption of its insulin pumps by type 1 and type 2 diabetic patients across all markets. The company is actively working with its product launch and commercial strategy to progress in the type 2 diabetes space. Accordingly, we expect the latest launch of Control-IQ+ technology to motivate market sentiment toward the TNDM stock to remain positive in the upcoming days.
Tandem Diabetes currently has a market capitalization of $1.33 billion. It has estimated earnings per share (EPS) growth rate of 38.7% in 2025 compared with the industry’s 15.6% growth. In the past 30 days, the company’s loss per share has decreased from $2.55 to $1.17 for 2025.
About TNDM’s Control-IQ+
Control-IQ+ is built on the existing features of Tandem Diabetes’ industry-leading Control-IQ algorithm. This is also the only AID algorithm that allows users to program extended boluses of up to 8 hours, to better manage delayed glucose rises or prolonged eating.
New features of the Control-IQ+ algorithm include expanded weight (20-440 lbs.) and total daily insulin (5-200 units) parameters to accommodate a wider range of insulin requirements. To address short-term glucose needs, such as exercise, stress, or illness, it comes with New Temp Basal Rate adjustments when Control-IQ+ is active. These new features allow greater levels of personalization and flexibility within the company’s algorithm, while still being easy to use for a diverse population of users.
In February, the technology achieved FDA approval for use by people with type 2 diabetes ages 18 and older.
Industry Prospects Favor TNDM
Per a report by Grand View Research, the global insulin delivery device market was valued at $16.43 billion in 2023 and is expected to witness a compound annual rate of 7.9% by 2027.
Image Source: Zacks Investment Research
The surge in market growth is primarily driven by the rising global prevalence of diabetes, which has created a greater need for advanced and user-friendly solutions for diabetes management. Technological advancements play a crucial role in the market growth, with devices becoming more effective, less invasive and personalized to meet patients' individual needs.
Other Developments by TNDM
In January, Tandem Diabetes signed a multi-year collaboration agreement with the University of Virginia Center for Diabetes Technology. The partnership will focus on advancing research and development efforts on fully automated closed-loop insulin delivery systems.
Additionally, in December 2024, the company’s t:slim X2 insulin pump became fully compatible with Dexcom G7 and Dexcom G6 Continuous Glucose Monitoring Systems, and is available for in-warranty users in Canada.
TNDM Stock Price Performance
In the past year, TNDM shares have declined 38.2% compared with the industry’s decline of 7.5%.
TNDM’s Zacks Rank and Key Picks
Tandem Diabetes Care currently carries a Zacks Rank #3 (Hold).
Masimo’s shares have rallied 26.5% in the past year. Estimates for MASI’s 2024 earnings per share (EPS) have increased 1.2% to $4.10 in the past 30 days. MASI’s earnings beat estimates in each of the trailing four quarters, the average surprise being 17.1%. In the last reported quarter, it posted an earnings surprise of 16.6%.
Estimates for Boston Scientific’s 2025 EPS have jumped 2.9% to $2.85 in the past 30 days. Shares of the company have surged 47.1% in the past year compared with the industry’s growth of 9.5%. BSX’s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 8.25%. In the last reported quarter, it delivered an earnings surprise of 7.69%.
Estimates for Cardinal Health’s fiscal 2025 EPS have increased 1.5% to $7.94 in the past 30 days. Shares of the company have jumped 17.5% in the past year against the industry’s 3.2% decline. CAH’s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 9.6%. In the last reported quarter, it delivered an earnings surprise of 10.3%.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
TNDM Stock Gains on the Commercial Launch of Control-IQ+ Technology
Tandem Diabetes Care, Inc. (TNDM - Free Report) recently commercially launched Control-IQ+ technology - the latest generation of its advanced hybrid closed-loop algorithm in the United States. Control-IQ+ is compatible with both the t:slim X2 insulin pump and Tandem Mobi System. It is available for people with type 1 diabetes (ages 2 years and older) and adults with type 2 diabetes.
TNDM Stock’s Likely Trend Following the News
Since the announcement, TNDM’s shares edged up 1.1% at the after-market trading yesterday.
Tandem Diabetes continues to strategically expand the adoption of its insulin pumps by type 1 and type 2 diabetic patients across all markets. The company is actively working with its product launch and commercial strategy to progress in the type 2 diabetes space. Accordingly, we expect the latest launch of Control-IQ+ technology to motivate market sentiment toward the TNDM stock to remain positive in the upcoming days.
Tandem Diabetes currently has a market capitalization of $1.33 billion. It has estimated earnings per share (EPS) growth rate of 38.7% in 2025 compared with the industry’s 15.6% growth. In the past 30 days, the company’s loss per share has decreased from $2.55 to $1.17 for 2025.
About TNDM’s Control-IQ+
Control-IQ+ is built on the existing features of Tandem Diabetes’ industry-leading Control-IQ algorithm. This is also the only AID algorithm that allows users to program extended boluses of up to 8 hours, to better manage delayed glucose rises or prolonged eating.
New features of the Control-IQ+ algorithm include expanded weight (20-440 lbs.) and total daily insulin (5-200 units) parameters to accommodate a wider range of insulin requirements. To address short-term glucose needs, such as exercise, stress, or illness, it comes with New Temp Basal Rate adjustments when Control-IQ+ is active. These new features allow greater levels of personalization and flexibility within the company’s algorithm, while still being easy to use for a diverse population of users.
In February, the technology achieved FDA approval for use by people with type 2 diabetes ages 18 and older.
Industry Prospects Favor TNDM
Per a report by Grand View Research, the global insulin delivery device market was valued at $16.43 billion in 2023 and is expected to witness a compound annual rate of 7.9% by 2027.
Image Source: Zacks Investment Research
The surge in market growth is primarily driven by the rising global prevalence of diabetes, which has created a greater need for advanced and user-friendly solutions for diabetes management. Technological advancements play a crucial role in the market growth, with devices becoming more effective, less invasive and personalized to meet patients' individual needs.
Other Developments by TNDM
In January, Tandem Diabetes signed a multi-year collaboration agreement with the University of Virginia Center for Diabetes Technology. The partnership will focus on advancing research and development efforts on fully automated closed-loop insulin delivery systems.
Additionally, in December 2024, the company’s t:slim X2 insulin pump became fully compatible with Dexcom G7 and Dexcom G6 Continuous Glucose Monitoring Systems, and is available for in-warranty users in Canada.
TNDM Stock Price Performance
In the past year, TNDM shares have declined 38.2% compared with the industry’s decline of 7.5%.
TNDM’s Zacks Rank and Key Picks
Tandem Diabetes Care currently carries a Zacks Rank #3 (Hold).
Some better-ranked stocks in the broader medical space are Masimo (MASI - Free Report) , Boston Scientific (BSX - Free Report) and Cardinal Health (CAH - Free Report) . At present, Masimo sports a Zacks Rank #1 (Strong Buy), whereas Boston Scientific and Cardinal Health carries a Zacks Rank #2 (Buy) each. You can see the complete list of today’s Zacks #1 Rank stocks here.
Masimo’s shares have rallied 26.5% in the past year. Estimates for MASI’s 2024 earnings per share (EPS) have increased 1.2% to $4.10 in the past 30 days. MASI’s earnings beat estimates in each of the trailing four quarters, the average surprise being 17.1%. In the last reported quarter, it posted an earnings surprise of 16.6%.
Estimates for Boston Scientific’s 2025 EPS have jumped 2.9% to $2.85 in the past 30 days. Shares of the company have surged 47.1% in the past year compared with the industry’s growth of 9.5%. BSX’s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 8.25%. In the last reported quarter, it delivered an earnings surprise of 7.69%.
Estimates for Cardinal Health’s fiscal 2025 EPS have increased 1.5% to $7.94 in the past 30 days. Shares of the company have jumped 17.5% in the past year against the industry’s 3.2% decline. CAH’s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 9.6%. In the last reported quarter, it delivered an earnings surprise of 10.3%.